Panagiotis Samaras
Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
Samaras P, Zander T, Taverna C, Schmidt A, Pabst T, Mey U, Matthes T, Lerch E, Ketterer N, Heim D, Duchosal M, Driessen C, Betticher D, Bargetzi M, Renner C. Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Med Wkly 2019; 149:w20031.
Apr 3, 2019Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
Apr 3, 2019Swiss Med Wkly 2019; 149:w20031
Samaras Panagiotis, Zander Thilo, Taverna Christian, Schmidt Adrian, Pabst Thomas, Mey Ulrich, Matthes Thomas, Lerch Erika, Ketterer Nicolas, Heim Dominik, Duchosal Michel A, Driessen Christoph, Betticher Daniel C, Bargetzi Mario, Renner Christoph
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study
Ghilardi G, Ghielmini M, Wannesson L, Lerch E, Samaras P, Schanz U, Passweg J, Stussi G, Kleber M, Gerber B, Rossi D, Schmidt A, Pabst T, Jeker B, Müller R, Cairoli A, Müller A, Bargetzi M, Hitz F, Baldomero H, Heim D, Swiss Blood Stem Cell Transplantation Registry. Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study. Bone Marrow Transplant 2018
Nov 2, 2018Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study
Nov 2, 2018Bone Marrow Transplant 2018
Ghilardi Guido, Ghielmini Michele, Wannesson Luciano, Lerch Erika, Samaras Panagiotis, Schanz Urs, Passweg Jakob R, Stussi Georg, Kleber Martina, Gerber Bernhard, Rossi Davide, Schmidt Adrian, Pabst Thomas, Jeker Barbara, Müller Rouven, Cairoli Anne, Müller Antonia M S, Bargetzi Mario, Hitz Felicitas, Baldomero Helen, Heim Dominik, Swiss Blood Stem Cell Transplantation Registry
Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma
Driessen C, Pabst T, Hitz F, Hawle H, Rondeau S, Berset C, Besse A, Besse L, Ribi K, Samaras P, Mey U, Rüfer A, Mach N, Betticher D, Cantoni N, Novak U, Müller R, Zander T. Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma. Blood 2018
Sep 20, 2018Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma
Sep 20, 2018Blood 2018
Driessen Christoph, Pabst Thomas, Hitz Felicitas, Hawle Hanne, Rondeau Stephanie, Berset Catherine, Besse Andrej, Besse Lenka, Ribi Karin, Samaras Panagiotis, Mey Ulrich, Rüfer Axel, Mach Nicolas, Betticher Daniel, Cantoni Nathan, Novak Urban, Müller Rouven, Zander Thilo
FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study.
Schneider P, Eshmuminov D, Rordorf T, Vetter D, Veit-Haibach P, Weber A, Bauerfeind P, Samaras P, Lehmann K. FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study. BMC cancer 2018; 18:548.
May 9, 2018FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study.
May 9, 2018BMC cancer 2018; 18:548
Schneider Paul M, Eshmuminov Dilmurodjon, Rordorf Tamara, Vetter Diana, Veit-Haibach Patrick, Weber Achim, Bauerfeind Peter, Samaras Panagiotis, Lehmann Kuno
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)
von Moos R, Plasswilm L, Zwahlen D, Meier U, Yan P, Izzo P, Klingbiel D, Bärtschi D, Zaugg K, Saletti P, Rauch D, Koeberle D, Schacher S, Hayoz S, Winterhalder R, Roth A, Bodoky G, Samaras P, Berger M, Swiss Group for Clinical Cancer Research (SAKK). Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08). Eur J Cancer 2017; 89:82-89.
Dec 11, 2017Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)
Dec 11, 2017Eur J Cancer 2017; 89:82-89
von Moos Roger, Plasswilm Ludwig, Zwahlen Daniel, Meier Urs R, Yan Pu, Izzo Paola, Klingbiel Dirk, Bärtschi Daniela, Zaugg Kathrin, Saletti Piercarlo, Rauch Daniel, Koeberle Dieter, Schacher Sabina, Hayoz Stefanie, Winterhalder Ralph C, Roth Arnaud, Bodoky György, Samaras Panagiotis, Berger Martin D, Swiss Group for Clinical Cancer Research (SAKK)
Nutritional support practices in hematopoietic stem cell transplantation centers: A nationwide comparison
Baumgartner A, Mueller B, Stanga Z, Hess U, Duchosal M, Pabst T, Wannesson L, Limonta A, Pichard C, Chalandon Y, Samaras P, Schanz U, Passweg J, Medinger M, Zueger N, Bargetzi A, Bargetzi M, Schuetz P. Nutritional support practices in hematopoietic stem cell transplantation centers: A nationwide comparison. Nutrition 2016; 35:43-50.
Oct 15, 2016Nutritional support practices in hematopoietic stem cell transplantation centers: A nationwide comparison
Oct 15, 2016Nutrition 2016; 35:43-50
Baumgartner Annic, Mueller Beat, Stanga Zeno, Hess Urs, Duchosal Michel A, Pabst Thomas, Wannesson Luciano, Limonta Alessandro, Pichard Claude, Chalandon Yves, Samaras Panagiotis, Schanz Urs, Passweg Jakob, Medinger Micheal, Zueger Noemi, Bargetzi Annika, Bargetzi Mario, Schuetz Philipp
Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience
Madanchi M, Rogler G, Vavricka S, Frei P, Biedermann L, Sulz M, Scharl S, Samaras P, Barthel C, Zeitz J, Scharl M. Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience. Digestion 2016; 94:1-8.
Jun 18, 2016Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience
Jun 18, 2016Digestion 2016; 94:1-8
Madanchi Mehdi, Rogler Gerhard, Vavricka Stephan R, Frei Pascal, Biedermann Luc, Sulz Michael, Scharl Sylvie, Samaras Panagiotis, Barthel Christiane, Zeitz Jonas, Scharl Michael
Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08
Hitz F, Rondeau S, Berardi Vilei S, Eckhardt K, Enoiu M, Rothermundt C, Schmidt A, Krasniqi F, Mach N, Caspar C, Samaras P, Cairoli A, Fischer N, Pabst T, Zucca E, Mey U. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08. Br J Haematol 2016
Mar 28, 2016Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08
Mar 28, 2016Br J Haematol 2016
Hitz Felicitas, Rondeau Stephanie, Berardi Vilei Simona, Eckhardt Katrin, Enoiu Milica, Rothermundt Christian, Schmidt Adrian, Krasniqi Fatime, Mach Nicolas, Caspar Clemens B, Samaras Panagiotis, Cairoli Anne, Fischer Natalie, Pabst Thomas, Zucca Emanuele, Mey Ulrich
Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
Samaras P, Zander T, Taverna C, Pabst T, Mey U, Matthes T, Lerch E, Ketterer N, Hess U, Heim D, Duchosal M, Betticher D, Bargetzi M, Renner C. Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Med Wkly 2015; 145:w14100.
Feb 21, 2015Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
Feb 21, 2015Swiss Med Wkly 2015; 145:w14100
Samaras Panagiotis, Zander Thilo, Taverna Christian, Pabst Thomas, Mey Ulrich, Matthes Thomas, Lerch Erika, Ketterer Nicolas, Hess Urs, Heim Dominik, Duchosal Michel A, Betticher Daniel C, Bargetzi Mario, Renner Christoph
Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation
Samaras P, Renner C, Stahel R, Knuth A, Taverna C, Schäfer N, Mischo A, Schanz U, Siciliano R, Honegger H, Haile S, Buset E, Petrausch U, Zardavas D, Stenner-Liewen F. Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation. Swiss Med Wkly 2013; 143:w13791.
May 7, 2013Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation
May 7, 2013Swiss Med Wkly 2013; 143:w13791
Samaras Panagiotis, Renner Christoph, Stahel Rolf, Knuth Alexander, Taverna Christian, Schäfer Niklaus G, Mischo Axel, Schanz Urs, Siciliano Raffaele D, Honegger Hanspeter, Haile Sarah, Buset Elefteri M, Petrausch Ulf, Zardavas Dimitrios, Stenner-Liewen Frank
Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone)
Wannesson L, Samaras P, Renner C, Pabst T, Lerch E, Hess U, Heim D, Cerutti A, Cairoli A, Bargetzi M, Zucca E. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone). Leuk Lymphoma 2012; 54:36-40.
Jul 9, 2012Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone)
Jul 9, 2012Leuk Lymphoma 2012; 54:36-40
Wannesson Luciano, Samaras Panagiotis, Renner Christoph, Pabst Thomas, Lerch Erika, Hess Urs, Heim Dominik, Cerutti Alessandra, Cairoli Anne, Bargetzi Mario, Zucca Emanuele
A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma
Stenner F, Renner C, Porta C, Buchler T, Knuth A, Stoll S, Siciliano R, Rothermundt C, Cathomas R, Haile S, Liewen H, Chastonay R, Samaras P. A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma. Oncology 2012; 82:333-340.
Jun 2, 2012A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma
Jun 2, 2012Oncology 2012; 82:333-340
Stenner Frank, Renner Christoph, Porta Camillo, Buchler Tomas, Knuth Alexander, Stoll Susanna, Siciliano Raffaele D, Rothermundt Christian, Cathomas Richard, Haile Sarah R, Liewen Heike, Chastonay Rahel, Samaras Panagiotis
Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience
Samaras P, Stenner-Liewen F, Knuth A, Bauer S, Taverna C, Stussi G, Schanz U, Honegger H, Zweifel M, Mischo A, Petrausch U, Siciliano R, Haile S, Blickenstorfer M, Renner C. Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. Swiss Med Wkly 2011; 141:w13203.
May 31, 2011Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience
May 31, 2011Swiss Med Wkly 2011; 141:w13203
Samaras Panagiotis, Stenner-Liewen Frank, Knuth Alexander, Bauer Stefan, Taverna Christian, Stussi Georg, Schanz Urs, Honegger Hanspeter, Zweifel Martin, Mischo Axel, Petrausch Ulf, Siciliano Raffaele Daniele, Haile Sarah, Blickenstorfer Marcel, Renner Christoph
Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases
Samaras P, Pestalozzi B, Knuth A, Renner C, Feilchenfeldt J, Heinrich S, Stenner-Liewen F, Haile S, Breitenstein S, Clavien P. Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases. Ann Surg Oncol 2011; 18:1924-31.
Jan 5, 2011Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases
Jan 5, 2011Ann Surg Oncol 2011; 18:1924-31
Samaras Panagiotis, Pestalozzi B C, Knuth A, Renner C, Feilchenfeldt J, Heinrich S, Stenner-Liewen F, Haile Sarah, Breitenstein S, Clavien P A
Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation
Samaras P, Renner C, Knuth A, Stahel R, Stussi G, Schanz U, Pestalozzi B, Honegger H, Mischo A, Petrausch U, Haile S, Siciliano R, Buset E, Stenner-Liewen F. Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation. Oncology 2010; 79:93-97.
Nov 15, 2010Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation
Nov 15, 2010Oncology 2010; 79:93-97
Samaras Panagiotis, Renner Christoph, Knuth Alexander, Stahel Rolf A, Stussi Georg, Schanz Urs, Pestalozzi Bernhard C, Honegger Hanspeter, Mischo Axel, Petrausch Ulf, Haile Sarah, Siciliano Raffaele Daniele, Buset Elefteri M, Stenner-Liewen Frank
Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim
Samaras P, Stenner-Liewen F, Knuth A, Stahel R, Stussi G, Schanz U, Honegger H, Mischo A, Petrausch U, Buset E, Haile S, Siciliano R, Blickenstorfer M, Renner C. Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. Ann Hematol 2010; 90:89-94.
Aug 13, 2010Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim
Aug 13, 2010Ann Hematol 2010; 90:89-94
Samaras Panagiotis, Stenner-Liewen Frank, Knuth Alexander, Stahel Rolf A, Stussi Georg, Schanz Urs, Honegger Hanspeter, Mischo Axel, Petrausch Ulf, Buset Elefteri M, Haile Sarah, Siciliano Raffaele Daniele, Blickenstorfer Marcel, Renner Christoph
Quantitative computed tomography liver perfusion imaging using dynamic spiral scanning with variable pitch: feasibility and initial results in patients with cancer metastases
Goetti R, Marincek B, Knuth A, Scheffel H, Stolzmann P, Reiner C, Stenner F, von Boehmer L, Samaras P, Klotz E, Desbiolles L, Leschka S, Alkadhi H. Quantitative computed tomography liver perfusion imaging using dynamic spiral scanning with variable pitch: feasibility and initial results in patients with cancer metastases. Invest Radiol 2010; 45:419-26.
Jul 1, 2010Quantitative computed tomography liver perfusion imaging using dynamic spiral scanning with variable pitch: feasibility and initial results in patients with cancer metastases
Jul 1, 2010Invest Radiol 2010; 45:419-26
Goetti Robert, Marincek Borut, Knuth Alexander, Scheffel Hans, Stolzmann Paul, Reiner Cäcilia, Stenner Frank, von Boehmer Lotta, Samaras Panagiotis, Klotz Ernst, Desbiolles Lotus, Leschka Sebastian, Alkadhi Hatem
Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP
Samaras P, Stenner-Liewen F, Knuth A, Zweifel M, Mischo A, Meisel A, Siciliano R, Schaefer N, Petrausch U, Haile S, Heider H, Renner C. Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. Ann Hematol 2010; 89:783-7.
Mar 5, 2010Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP
Mar 5, 2010Ann Hematol 2010; 89:783-7
Samaras Panagiotis, Stenner-Liewen Frank, Knuth Alexander, Zweifel Martin, Mischo Axel, Meisel Alexander, Siciliano Raffaele Daniele, Schaefer Niklaus G, Petrausch Ulf, Haile Sarah, Heider Helen, Renner Christoph
Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas
Riener M, Jochum W, Moch H, Fritzsche F, Wild P, Neuhaus P, Bahra M, Clavien P, Mullhaupt B, Hellerbrand C, Probst-Hensch N, Samaras P, Pestalozzi B, Breitenstein S, Soll C, Liewen H, Stenner F, Kristiansen G. Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology (Baltimore, Md.) 2009; 49:1602-9.
May 1, 2009Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas
May 1, 2009Hepatology (Baltimore, Md.) 2009; 49:1602-9
Riener Marc-Oliver, Jochum Wolfram, Moch Holger, Fritzsche Florian, Wild Peter, Neuhaus Peter, Bahra Marcus, Clavien Pierre-Alain, Mullhaupt Beat, Hellerbrand Claus, Probst-Hensch Nicole, Samaras Panagiotis, Pestalozzi Bernhard Cornelius, Breitenstein Stefan, Soll Christopher, Liewen Heike, Stenner Frank, Kristiansen Glen